Glp1 Pharmaceutical Compositions

Abstract: The present invention relates to an oral capsule composition comprising 3-[(1S,2S)-1-[5-[(4S)-2,2-dimethyloxan-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4H-1,2,4-oxadiazol-5-one,or a pharmaceutically acceptable salt thereof; and a pH modifier.

Patent Information

Application #

Filing Date

05 November 2024

Publication Number

51/2024

Publication Type

INA

Invention Field

CHEMICAL

Status

Email

Parent Application

Applicants

ELI LILLY AND COMPANY

Lilly Corporate Center Indianapolis, Indiana 46206-6288

Inventors

1. BURNS, Lee Joseph

c/o ELI LILLY AND COMPANY P.O. Box 6288 Indianapolis, Indiana 46206-6288

Specification

Documents

Application Documents

#	Name	Date
1	202417084468-STATEMENT OF UNDERTAKING (FORM 3) [05-11-2024(online)].pdf	2024-11-05
2	202417084468-PRIORITY DOCUMENTS [05-11-2024(online)].pdf	2024-11-05
3	202417084468-POWER OF AUTHORITY [05-11-2024(online)].pdf	2024-11-05
4	202417084468-FORM 1 [05-11-2024(online)].pdf	2024-11-05
5	202417084468-FIGURE OF ABSTRACT [05-11-2024(online)].pdf	2024-11-05
6	202417084468-DECLARATION OF INVENTORSHIP (FORM 5) [05-11-2024(online)].pdf	2024-11-05
7	202417084468-COMPLETE SPECIFICATION [05-11-2024(online)].pdf	2024-11-05
8	202417084468-MARKED COPIES OF AMENDEMENTS [06-11-2024(online)].pdf	2024-11-06
9	202417084468-FORM 18 [06-11-2024(online)].pdf	2024-11-06
10	202417084468-FORM 13 [06-11-2024(online)].pdf	2024-11-06
11	202417084468-AMMENDED DOCUMENTS [06-11-2024(online)].pdf	2024-11-06
12	202417084468-Proof of Right [14-11-2024(online)].pdf	2024-11-14
13	202417084468-FORM 3 [03-04-2025(online)].pdf	2025-04-03